多西紫杉醇联合长春瑞滨治疗晚期非小细胞肺癌48例疗效观察  

Clinical Study on Docetaxel Plus Vinorelbine in 48 Patients with Advanced Non-Small Cell Lung Cancer

作　　者：宋德刚[1] 刘杰[1] 王哲海[1] 李长征[1] 郭珺[1] 陈阵[1] 石焕[1] 

机构地区：[1]山东省肿瘤医院内三科,250117

出　　处：《实用癌症杂志》2007年第5期483-485,共3页The Practical Journal of Cancer

摘　　要：目的观察国产多西紫杉醇(艾素)联合国产长春瑞滨(盖诺)二线治疗晚期非小细胞肺癌(NSCLC)48例临床疗效和不良反应。方法48例均为一线治疗失败的患者,经病理组织学或细胞学检查证实为NSCLC,给予国产多西紫杉醇(艾素)60mg/m2,静脉滴注,第1天;国产长春瑞滨(盖诺)25mg/m2,静脉滴注,第1、5天,每3周重复。治疗2个周期后评价疗效和不良反应。结果48例患者治疗后CR1例,PR16例,总有效率为35.4%(17/48)。最常见的血液系统不良反应有中性粒细胞减少(60.4%),中性粒细胞减少性发热(29.2%),非血液毒性温和,耐受良好。结论国产多西紫杉醇(艾素)联合国产长春瑞滨(盖诺)治疗晚期非小细胞肺癌显示出较好的疗效和安全性。Objective To evaluate the efficacy and safety of the second-line treatment of advanced non-small cell lung cancer with docetaxel plus vinorelbine. Methods 48 histologically or cytologically confirmed non-small cell lung cancer patients with progressive disease after first-llne treatment were treated with docetaxel plus vinorelbine. The chemotherapy included vinorelbine （25 mg/m^2） on days 1,5 and docetaxel （60 mg/m^2） on day 1. The treatment was repeated every 3 weeks. Patients receiving at least two cycles were evaluated for toxicity and efficacy. Results Of 48 patients, 1 patient achieved complete response and 16 achieved partial response. Overall response rate for all 48 patients was 35.4% （ 17/48 ）. Main hematologic toxicities included neutropenia （60.4%） and febrile neutropenia （29.2%） and non-hematologic toxicities were mild. Conclusion This schedule of docetaxel and vinorelbine combination is effective and safety. Further studies may confirm these results.

关 键 词：多西紫杉醇 长春瑞滨 联合化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]